Bristol-Myers Squibb (BMY) EPS (2010 - 2026)
Bristol-Myers Squibb (BMY) EPS from Mar 31, 2010 to Mar 31, 2026. The TTM Bristol-Myers Squibb (BMY) EPS is $4.25. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EPS
Quarterly EPS
Bristol-Myers Squibb (BMY) EPS CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +15.30% |
| 3 Years TTM | +6.76% |
| 5 Years TTM | +12.37% |
| 10 Years TTM | +11.09% |
| All Time TTM | +4.06% |
Annual EPS change of Bristol-Myers Squibb (BMY)
| Year | EPS | Change |
|---|---|---|
| 2026 | $1.31 | -62.12% |
| 2025 | $3.47 | -178.56% |
| 2024 | -$4.41 | -213.81% |
| 2023 | $3.88 | +30.58% |
| 2022 | $2.97 | -5.67% |
| 2021 | $3.15 | -178.87% |
| 2020 | -$3.99 | -297.94% |
| 2019 | $2.02 | -33.05% |
| 2018 | $3.01 | +392.17% |
| 2017 | $0.61 | -77.05% |
| 2016 | $2.67 | +184.11% |
| 2015 | $0.94 | -22.37% |
| 2014 | $1.21 | -22.42% |
| 2013 | $1.56 | +32.83% |
| 2012 | $1.17 | -46.21% |
| 2011 | $2.18 | +20.48% |
| 2010 | $1.81 | -66.32% |
| 2009 | $5.38 | N/A |
Comparison Bristol-Myers Squibb (BMY) five years EPS CAGR with competitors
Bristol-Myers Squibb (BMY) five years EPS CAGR is 5.08%.
| Ticker | Name | five years EPS CAGR | Upside |
|---|---|---|---|
| GILD | Gilead Sciences Inc | 98.59% | +1839.90% |
| LLY | Lilly(Eli) & Company | 29.14% | +473.41% |
| NVO | Novo Nordisk | 24.26% | +377.28% |
| AZN | Astrazeneca plc | 17.09% | +236.34% |
| NVS | Novartis AG | 14.96% | +194.34% |
| JNJ | Johnson & Johnson | 11.59% | +128.03% |
| MRK | Merck & Co Inc | 5.37% | +5.70% |
| GSK | GSK Plc | 4.65% | -8.47% |
| AMGN | AMGEN Inc | 3.49% | -31.23% |